Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Adenine
/ analogs & derivatives
Adult
Arthralgia
/ chemically induced
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ complications
Lymphoma, Mantle-Cell
/ drug therapy
Musculoskeletal Pain
/ chemically induced
Myalgia
/ chemically induced
Piperidines
Protein Kinase Inhibitors
/ adverse effects
Pyrazoles
/ adverse effects
Pyrimidines
/ adverse effects
Ibrutinib
arthralgia
chronic lymphocytic leukemia
mantle cell lymphoma
musculoskeletal pain
myalgia
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
2
3
2022
medline:
14
7
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
Joint and muscle pain, including arthralgia, myalgia, and musculoskeletal pain, are among the common adverse events (AEs) reported for ibrutinib, a once-daily Bruton's tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This pooled analysis from nine clinical trials of ibrutinib in CLL and MCL (
Identifiants
pubmed: 35227147
doi: 10.1080/10428194.2022.2038372
doi:
Substances chimiques
Piperidines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM